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FGF21 is a unique member of the ﬁbroblast growth factors (FGFs) and a novel hormone that regu-
lates glucose, lipid, and energy homeostasis. The beneﬁcial effects of FGF21 reported thus far have
mostly been from chronic treatments. In order to better understand the mechanism for FGF21
action, we evaluated the acute effects of FGF21 in vivo and in vitro. Here we report that a single
injection of FGF21 acutely reduced plasma free fatty acid levels similar to its acute effects on plasma
glucose in ob/ob mice. In vitro, FGF21 inhibited lipolysis in adipocytes during a short treatment and
reduced total lipase activity. These results demonstrate the potential importance of adipocyte lipol-
ysis to the observed acute improvements in plasma parameters.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
FGF21 is a unique member of ﬁbroblast growth factors (FGFs)
and has emerged as an important metabolic hormone that is in-
volved in the regulation of energy and glucose homeostasis [1,2].
The chronic effects of FGF21 on various metabolic parameters in
several different disease models have been very impressive.
FGF21 transgenic mice showed resistance to the effects of a high-
fat high-calorie diet [1]. Chronic treatment with recombinant
FGF21 has been shown to signiﬁcantly reduce blood glucose levels
without hypoglycemia in ob/ob, db/db and diet-induced-obesity
(DIO) mice [1,3,4]. Improvements in glucose disposal and plasma
lipid proﬁles have also been observed. In addition, all these bene-
ﬁts are accompanied by a signiﬁcant weight loss due to increased
energy expenditure without observed reduction in food intake.
Furthermore, a recent study showed that FGF21 treatment im-
proved glucose, insulin and lipid proﬁles, and reduced body weight
of diabetic rhesus monkeys [5]. Therefore, FGF21 has the potential
to be a novel therapy for the treatment of diabetes and obesity.chemical Societies. Published by E
free fatty acidRecent progress has been made in the elucidation of receptor
complexes and cellular functions for FGF21. In vitro studies suggest
that in addition to the tyrosine kinase FGF receptors (FGFRs), b-
Klotho (a single-pass transmembrane glycoprotein) is required as
a co-receptor for FGF21 signaling on the cell surface [6–8]. Expres-
sion patterns of receptors may determine the target tissue speciﬁc-
ity for FGF21 function. b-Klotho is predominantly expressed in
metabolic organs including adipose tissue, liver, and pancreas,
and direct effects of FGF21 on these cells have been demonstrated
[3,6]. In adipocytes, FGF21 has been shown to stimulate glucose
uptake independent of insulin, but these effects required overnight
treatment with the protein and were dependent upon the in-
creased transcription of glucose transporter GLUT1 [1]. However,
these previous in vitro and in vivo studies have focused primarily
on chronic or sub-chronic effects of FGF21. Studying acute re-
sponses will facilitate the understanding of the mechanism of ac-
tion and to separate direct from secondary effects of FGF21
treatment.
In the current study, we sought to determine if FGF21 could
acutely regulate lipid parameters. Here we report that a single
intraperitoneal (i.p.) injection of FGF21 acutely lowered plasma
glucose and free fatty acid (FFA) levels. In vitro, a short FGF21
treatment also inhibited lipolysis in adipocytes.lsevier B.V. All rights reserved.






















Fig. 1. Single injection of hFGF21 into ob/ob mice acutely reduces blood glucose.
Age matched ob/ob mice were fed with normal chow overnight and their blood
glucose measured in the morning. The mice were divided into two group (n = 10 in
each group) based on their blood glucose and body weight. Compare to the control
group (PBS at 5 ml/kg body weight), single injection of 1 mg/ml FGF21 (5 ml/kg
body weight) acutely reduced the blood glucose. The glucose lower effect of FGF21
lasted more than 6 h in these mice. ***P < 0.001.
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2.1. FGF21 protein
Recombinant human FGF21 protein (amino acids 29–208 with-
out signal peptide) was expressed and puriﬁed from an Escherichia
coli strain as previously described [3].
2.2. Glucose uptake assay
3T3L1 preadipocytes (ATCC CL-173) were cultured and induced
to differentiate as follows: cells were plated in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) with 10% fetal FBS and 1% Pen-Strep at a
density of 25000 cells per well on 96-well Cytostar-T scintillating
microplates (GE Healthcare). Two days after reaching conﬂuence,
differentiationwas induced by adding 250 nMdexamethasone (Sig-
ma), 500 lM isobutylmethylxanthine (Sigma) and 1 lg/ml insulin
(Sigma) for 2 days. The cells were then cultured in DMEM with
10% FBS, 1% Pen-Strep and 1 lg/ml insulin for 2 days, and thenwith-
out insulin for an additional 3 days. Differentiated adipocytes were
washed once with DMEM containing 1% FBS and 1% Pen-Strep.
Treatments were added to the adipocytes at the indicated concen-
trations and incubated for 4–72 h. The cells were then washed once
with glucose-free DMEM (Invitrogen) containing 0.1% fatty-acid
free BSA, and treatments were added to the cells at the indicated
concentrations in the same medium for 3 h. The cells were then
washed twice with Krebs–Ringer Phosphate Buffer (KRP) composed
of 118 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM KH2PO4,
1.2 mMMgSO4 and 15 mMHEPES (pH 7.4), with 0.1% fatty-acid free
BSA. 2-Deoxyglucose-1-3H (Sigma) was added to the cells at a con-
centration of 0.2 lCi per well and incubated for an additional 1 h at
37 C. Cytochalasin B (50 lM) (Sigma) was added to the cells to ter-
minate the reaction and deoxyglucose uptake was measured on a
Wallac MicroBeta (Perkin Elmer). Non-speciﬁc deoxyglucose up-
take was measured in the presence of 50 lM cytochalasin B and
subtracted from each sample to obtain speciﬁc uptake.
2.3. FGF21 treatment in mice
Aged matched C57Bl/6 or ob/ob mice were used in all the stud-
ies. Puriﬁed FGF21 or vehicle (PBS) were intraperitoneally (i.p.) in-
jected into mice at stated concentrations. After indicated time,
blood was collected by tail bleeding and blood glucose was mea-
sured with a glucose meter. Plasma FFA levels were measured
using the Wako HR Series FFA-HR [2] kit following the manufac-
turer’s instruction.
2.4. Lipolysis assay in differentiated 3T3L1 cells and primary
adipocytes isolated from mice
3T3L1 cells (ATCC CL-173) were cultured and differentiated, and
primary adipocytes were isolated from mice following protocols as
previously described [9]. Adipocytes were then treated with FGF21
in KRH buffer for indicated times. Glycerol released from lipolysis
during treatment was measured by Free Glycerol Reagent (Sigma
F6428), and cells were used to measure the total lipase activity.
2.5. Total lipase activity measurement
Cells were treated with lysis buffer (0.25 M sucrose, 50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA). Cell lysate was cen-
trifuged at 10000g for 30 min at 4 C. The upper level fat cake
was removed and the clear supernatant was used to measure the
total lipase activity. The lipase activity was measured using a ﬂuo-
rescent substrate from a lipase assay kit according to the manufac-
turer’s instructions (Roar Biomedicals, RB- LPL2).3. Results
3.1. Single injection of FGF21 into ob/ob mice acutely reduced blood
glucose levels
Chronic studies have shown that FGF21 treatment for over 3
weeks, delivered by daily s.c. injection or by miniosmotic pump,
lowered blood glucose levels and corrected obesity in ob/ob or
DIO mice [1,3,4]. We have recently observed an acute effect of
FGF19 on lowering blood glucose levels [10]. FGF21 was injected
intraperitoneally (i.p.) at 5 mg/kg body weight into ob/ob mice
and blood glucose levels were measured at 1, 3, 6, and 24 h post
injection. Comparing to the PBS control group, similar to recent
observation, a single i.p. injection of FGF21 resulted in a signiﬁcant
reduction in blood glucose levels, with approximately 40% reduc-
tion achieved 1 h post injection. This effect lasted up to 6 h and dis-
appeared 24 h post injection (Fig. 1).
3.2. Acute FGF21 treatment inhibits lipolysis in primary adipocytes and
differentiated 3T3L1 cells
We sought to explore potential mechanisms that might contrib-
ute to the acute lowering of plasma glucose levels by examining the
effects of FGF21 on the functions of different cell types in vitro. We
ﬁrst tested effects of FGF21 on adipocyte functions given receptor
expression and the well-established effects of FGF21 on the stimu-
lation of glucose uptake into these cells [1]. The stimulated glucose
uptake into 3T3L1 murine adipocyte cells reported previously was
after 24 h treatment of the cells with FGF21 [1]. To explore whether
this stimulation could occur acutely, we performed a time course
experiment varying the length of FGF21 treatment prior to measur-
ing the rate of glucose uptake. As shown in Fig. 2A, a treatment of
3T3L1 adipocytes with FGF21 for 4 h did not signiﬁcantly stimulate
glucose uptake into these cells. Signiﬁcant stimulation was not ob-
served until 72 h post FGF21 treatment (Fig. 2A). This is consistent
with the previous hypothesis that transcriptional events, for exam-
ple, the induction of GLUT1 expression, are needed to mediate the
effects of FGF21 [1]. However, this suggests that the stimulation of
glucose uptake into adipocyte may not fully explain the acute glu-
cose lowering effect of FGF21 treatment in vivo.
Several previous reports also suggest that FGF21 may regulate
adipocyte lipolysis as well [11,12] and adipocyte lipolysis could af-
fect circulating FFA levels [13]. FFAs are not only energy substrates,
but are also signaling molecules that may inﬂuence metabolic
homeostasis. Elevated FFA levels could impair glucose and lipid
metabolism in liver, muscle, pancreas, and might induce insulin





























































































































Fig. 2. Acute FGF21 treatment inhibits lipolysis in differentiated 3T3L1 cells and primary adipocytes. Differentiated 3T3L1 adipocytes (A, D, E) and isolated primary
adipocytes (B and C) were treated with FGF21 or PBS. Glucose uptake in 3T3L1 cells was measured at 4 h or 72 h post FGF21 treatment (A). The acute effects of FGF21
treatments on lipolysis were measured 4 h post FGF21 treatment in primary adipocytes (B) and in 3T3L1 adipocytes (D). The lipolysis suppression effect is accompanied by
the reduction of the totally lipase activity in primary adipocytes (C) and in 3T3L1 adipocytes (E). *P < 0.05; **P < 0.01; and ***P < 0.001.
3232 X. Li et al. / FEBS Letters 583 (2009) 3230–3234resistance [14,15]. FFAs could also serve as liver substrate for glu-
coneogenesis and very low density lipoprotein production, and
that in the diabetic state, gluconeogenesis is highly increased and
contributes to the elevated blood glucose levels [16]. We, there-
fore, explored whether FGF21 could acutely regulate adipocyte
lipolysis and whether this might contribute to the observed acute
lowering of plasma glucose by FGF21 treatment in vivo.
Isolated mouse primary adipocyte cells were treated with
FGF21 or PBS and the lipolysis rates in these cells were measured
by the release of glycerol into the culture medium. As shown in
Fig. 2B, FGF21 treatment inhibited lipolysis in mouse primary adi-
pocytes. The inhibition of lipolysis by FGF21 could be observed as
early as 1 h post treatment (data not shown) but was more pro-
nounced between 4 and 6 h of treatment when 30% inhibition of
lipolysis was observed (Fig. 2B). The lipolysis suppression effect
is accompanied with the reduction of the total lipase activity in
these cells (Fig. 2C). FGF21 treatment in differentiated 3T3L1 cells
had the same inhibitory effects on lipolysis and total lipase activity(Fig. 2D and E). These data indicated that in adipose tissue, acute
treatment of FGF21 leads to inhibition of total lipase activity and
lipolysis.
3.3. Administration of FGF21 acutely lowered plasma FFA in both wild-
type (wt) and ob/ob mice
Since the rate of adipocyte lipolysis could regulate plasma FFA
levels, we next explored the acute effects of FGF21 treatment on
plasma FFA levels in vivo. FGF21 was injected i.p. at 5 mg/kg body
weight into both wt and ob/ob mice. Plasma samples were col-
lected 0.5, 1 and 5 h after injection and FFA levels in the plasma
were measured. Single injection of FGF21 into wt mice resulted
in a rapid reduction in plasma FFA levels 30 min after the injection
(Fig. 3A). The reduction in plasma FFA levels was also observed in
ob/ob mice treated with FGF21, and the peak reduction was 1 h
after injection, which corresponded to the timing of the glucose
lowering effect of FGF21 (Fig. 3B). To provide further evidence










































Fig. 3. Acute administration of FGF21 lowers plasma FFA in both wt and ob/obmice.
Age matched wt (A) or ob/ob (B) mice were fasted overnight. The mice were divided
into two groups (n = 10 in each group) based on body weight. Compared to the
control group (PBS at 5 ml/kg body weight), a single i.p. injection of 1 mg/ml FGF21
(5 ml/kg body weight) acutely reduced FFA levels in both wt (A) and ob/ob (B) mice.















































Fig. 4. Dose–response studies of FGF21 administration in ob/ob mice. Age matched
ob/ob mice were divided into groups (n = 10 in each group) based on body weight.
(A) Dose–response effects of FGF21 administration on plasma glucose levels. Mice
were injected with indicated concentration of FGF21 (10 ml/kg body weight)
similar to Fig. 1. Blood glucose levels were measured at 0, 1, 3, and 5 h post
injection. The area under the curve (AUC) of the blood glucose during this period is
shown. (B) Dose–response effects of FGF21 administration on plasma FFA levels.
Mice were injected with indicated concentration of FGF21 (10 ml/kg body weight)
similar to Fig. 3. Plasma FFA levels were measured before and 1 h after injection.
The changes in FFA levels relative to PBS control group are shown. *P < 0.05;
**P < 0.01; ***P < 0.001.
X. Li et al. / FEBS Letters 583 (2009) 3230–3234 3233for the potential link between the effects of FGF21 on plasma FFA
and glucose, dose–response studies were carried out. FGF21 was
injected i.p. between 0.005 mg/kg and 5 mg/kg body weight into
ob/ob mice. As shown in Fig. 4, the potency of FGF21 induced
reduction in plasma glucose levels (Fig. 4A) is consistent with the
potency of its effects on reducing plasma FFA levels (Fig. 4B), and
this is also in general agreement with previously published dose–
responses of FGF21 in chronic studies [4,17]. This indicated that
FGF21 treatment could suppress plasma FFA levels and this may
have contributed to the acute reduction in blood glucose levels.
4. Discussion
FGF21 has emerged as an important metabolic regulator. Stud-
ies in multiple animal models have demonstrated the efﬁcient and
beneﬁcial effects of FGF21 on glucose and lipid homeostasis. How-
ever, majority of the studies reported so far have been chronic
studies, acute effects of FGF21 treatment have not been fully char-
acterized. In this report, we studied the acute effects of FGF21 on
plasma lipid parameters and found that a single FGF21 injection
lowered plasma FFA levels similar to its acute effects on glucose
as early as 1 h post injection in ob/ob mice.
In order to gain insights into the underlying mechanism for
these observed acute effects, we explored the short term responses
to FGF21 on metabolically relevant cell types. Since adipocytes
have been shown to be a potential target tissue for FGF21, we ex-
plored whether regulation of adipocyte function might contribute
to the observed acute effects of FGF21 in vivo. Consistent with pre-
vious reports, we show that signiﬁcant glucose uptake into adipo-
cyte does not occur post a transient treatment with FGF21. This
agrees with the suggestion that stimulation of glucose uptake
might be the result of transcriptional changes and upregulationof GLUT1 transporter in these cells [1]. This suggests that increased
glucose uptake into adipocytes might not be the main contributor
to the acute reduction in plasma glucose levels in vivo.
The reported effects of FGF21 on lipolysis has been inconsis-
tent in the literature, both transient increase in lipolysis [11]
and chronic inhibition of lipolysis [12] have been reported. To
clarify the effects of FGF21 on adipocyte lipolysis, we examined
the effects of FGF21 treatment on both the 3T3L1 adipocyte cells
differentiated in vitro as well as primary adipocytes isolated from
animals. Our results indicate that FGF21 treatment could inhibit
adipocyte lipolysis after a short treatment in both the primary
and the in vitro differentiated adipocyte cells. Such inhibition
might be the result of inhibition of the lipase function as a reduc-
tion of total lipase activity was observed with FGF21 treatment
(Fig. 2). Adipocyte lipolysis could regulate plasma FFA levels,
and we have observed an acute reduction in plasma FFA levels
post FGF21 injection in both wt and ob/ob mice (Fig. 3). The inhi-
bition of adipocyte lipolysis by FGF21 in vitro could be observed
as early as 1 h post treatment and become more pronounced at
4 h post treatment (Fig. 2). However, its ability to reduce plasma
FFA levels peaked at 1 h post injection and disappeared at later
time points (Fig. 3). This difference in timing of effects could be
the result of differences in the state of adipocyte in vivo vs.
in vitro. Alternatively, the stability of FGF21 in the different con-
ditions could also contribute to the apparent disconnect in timing,
the reported FGF21 plasma half life after a single i.v. or s.c. admin-
istration is less than 1 h in mice and its stability could be longer in
culture media [5].
3234 X. Li et al. / FEBS Letters 583 (2009) 3230–3234It has been reported that during the fasting state, more than 30%
of gluconeogenesis comes from FFAs as substrates [13]. In diabetes,
dysregulated insulin and glucagon levels and hepatic insulin resis-
tance results in highly increased hepatic gluconeogenesis and con-
tribute signiﬁcantly to the elevated blood glucose levels [13].
Therefore, we propose that the acute reduction in plasma FFA lev-
els post FGF21 treatment could lead to a reduction in gluconeogen-
esis. Lowered FFA levels may also improve muscle glucose
utilization and liver insulin sensitivity [18]. This potential link is
further supported by the similar dose–responses to FGF21 treat-
ment in affecting plasma glucose and FFA levels (Fig. 4). The
dose–responses of acute effects of FGF21 is also in general agree-
ment with the dose–responses observed in chronic FGF21 studies
reported previously on plasma glucose and lipid parameters
[4,17], suggesting that the acute effects of FGF21 observed here
may contribute to the chronic effects of FGF21. It is interesting to
note that recent data may also support a direct effect of FGF21
on liver function [19]. Berglund et al. have recently reported the ef-
fects of acute 6 h infusion of FGF21 in ob/+ and ob/ob mice [19].
Their results showed a potent effect of FGF21 on the liver glucose
ﬂux and reported a reduction in liver triglyceride and an increase
in liver glycogen content in the absence of changes in plasma insu-
lin, FFA levels, or skeletal muscle and adipose glucose uptake, sug-
gesting a direct effect of FGF21 on the liver [19]. It is possible that
the combination of indirect effects on hepatic gluconeogenesis
from the suppression of lipolysis and plasma FFA levels and a direct
inhibition of glucose output from liver may explain the acute effect
on lowering plasma glucose levels by FGF21.Acknowledgements
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